Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in <i>PBRM1</i> and <i>BAP1</i> with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.
Martin H. Voss(Memorial Sloan Kettering Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Nadeem Riaz(Memorial Sloan Kettering Cancer Center), Toni K. Choueiri(Harvard University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Timothy A. Chan(Cleveland Clinic), Parul Patel(Novartis (United States)), David Chen(Novartis (United States)), Fengshen Kuo(Memorial Sloan Kettering Cancer Center), Mahtab Marker(Novartis (United States)), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center)
Cited by 28
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k